Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=10 Diagnostic

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

Lymphoma

Bottom Line

View on ClinicalTrials.gov: NCT01004718 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fludeoxyglucose F18 (Radiation); Computed Tomography (Procedure); Positron emission tomography (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abramson Cancer Center at Penn Medicine
Primary completion
Jul 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration		 36.2; 32 —

Summary

RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

Eligibility Criteria

Inclusion Criteria

  • Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.

Exclusion Criteria

  • Pregnant or nursing,
  • Uncontrolled diabetes mellitus,
  • Active infection,
  • Inability to give informed consent or to comply with all study procedures,
  • Subjects may be excluded at the discretion of the principal investigator or study team members.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01004718). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search